| 臺大學術典藏 |
2022-09-15T01:09:04Z |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
|
Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; Chia-Chi Lin; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. |
| 國立成功大學 |
2022 |
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
|
Harrison, S.A.;Manghi, F.P.;Smith, W.B.;Alpenidze, D.;Aizenberg, D.;Klarenbeek, N.;Chen, Chen C.-Y.;Zuckerman, E.;Ravussin, E.;Charatcharoenwitthaya, P.;Cheng, P.-N.;Katchman, H.;Klein, S.;Ben-Ari, Z.;Mendonza, A.E.;Zhang, Y.;Martic, Martic M.;Ma, S.;Kao, S.;Tanner, S.;Pachori, A.;Badman, M.K.;He, Y.L.;Ukomadu, C.;Sicard, E. |
| 臺大學術典藏 |
2021-10-14T02:45:47Z |
Benign prostatic enlargement is not associated with diabetes: A population-based study
|
Chiu Y.L.; Kao S.; Lin H.C.; Liu S.P.; CHAO-YUAN HUANG |
| 臺大學術典藏 |
2021-02-02T07:50:57Z |
An appendectomy increases the risk of rheumatoid arthritis: A five-year follow-up study
|
Tzeng Y.-M.; Kao L.-T.; Kao S.; Lin H.-C.; Tsai M.-C.; Lee, Cha-Ze |
| 臺大學術典藏 |
2021-02-02T07:50:55Z |
Healthcare service utilization for practicing physicians: A population-based study
|
Chiu Y.-L.; Kao S.; Lin H.-C.; Tsai M.-C.; Lee, Cha-Ze |
| 臺大學術典藏 |
2021-01-29T03:17:18Z |
Benign prostatic enlargement is not associated with diabetes: A population-based study
|
Chiu Y.L.;Kao S.;Lin H.C.;Shih-Ping Liu;Huang C.Y.; Chiu Y.L.; Kao S.; Lin H.C.; SHIH-PING LIU; Huang C.Y. |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Yang J.C.-H.; Yang Z; Overend P; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; John T; Kim H.R; Chia-Chi Lin; Kim T.M; Ahn J.-S; Lee J.S; Kim S.-W; Cho B.C; Kim D.-W; Ahn M.-J |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non�Vsmall-cell lung cancer
|
Shaw A.T; Solomon B.J; Besse B; Bauer T.M; Chia-Chi Lin; Soo R.A; Riely G.J; Ignatius Ou S.-H; Clancy J.S; Li S; Abbattista A; Thurm H; Satouchi M; Camidge D.R; Kao S; Chiari R; Gadgeel S.M; Felip E; Martini J.-F. |
